Maria Caterina Micò

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

Alessandro Rambaldi, Anna Grassi, Arianna Masciulli et al. · The Lancet Oncology · 2015 · 179 citations · Full text

Medicine, Hematology, Pharmacology +17

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 154 citations · Full text

Medicine, Hematology, Immunology +17

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Alessandro Rambaldi, Giuseppe Gritti, Maria Caterina Micò et al. · Immunobiology · 2020 · 153 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +16

Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience

Marta Castelli, Maria Caterina Micò, Anna Grassi et al. · Bone Marrow Transplantation · 2024 · 19 citations · Full text

Life Sciences, Hematology, Immunology +14

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Robert Zeiser, Raynier Devillier, Maria Caterina Micò et al. · Blood · 2023 · 14 citations

Life Sciences, Immunology, Pharmacotherapy +17